Skip to main content

Advertisement

SpringerLink
Log in

Osteogenesis Imperfecta Type VI in Individuals from Northern Canada

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Osteogenesis imperfecta (OI) type VI is a recessively inherited form of OI that is caused by mutations in SERPINF1, the gene coding for pigment-epithelium derived factor (PEDF). Here, we report on two apparently unrelated children with OI type VI who had the same unusual homozygous variant in intron 6 of SERPINF1 (c.787-10C>G). This variant created a novel splice site that led to the in-frame addition of three amino acids to PEDF (p.Lys262_Ile263insLeuSerGln). Western blotting showed that skin fibroblasts with this mutation produced PEDF but failed to secrete it. Both children were treated with intravenous bisphosphonates, but the treatment of Individual 1 was switched to subcutaneous injections of denosumab (dose 1 mg per kg body weight, repeated every 3 months). An iliac bone sample obtained after 5 denosumab injections (and 3 months after the last injection) showed no change in the increased osteoid parameters that are typical of OI type VI, but the number of osteoclasts in trabecular bone was markedly increased. This suggests that the effect of denosumab on osteoclast suppression is of shorter duration in children with OI type VI than what has previously been reported on adults with osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30–38

    Article  PubMed  Google Scholar 

  2. Land C, Rauch F, Travers R, Glorieux FH (2007) Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 40:638–644

    Article  CAS  PubMed  Google Scholar 

  3. Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E (2012) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12:183–188

    CAS  PubMed  Google Scholar 

  4. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S, Travers R, Glorieux FH, Lee B (2011) Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res 26:2798–2803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rauch F, Husseini A, Roughley P, Glorieux FH, Moffatt P (2012) Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI. J Clin Endocrinol Metab 97:E1550–E1556

    Article  CAS  PubMed  Google Scholar 

  6. Al-Jallad H, Palomo T, Roughley P, Glorieux FH, McKee MD, Moffatt P, Rauch F (2015) The effect of SERPINF1 in-frame mutations in osteogenesis imperfecta type VI. Bone 76:115–120

    Article  CAS  PubMed  Google Scholar 

  7. Al-Jallad H, Palomo T, Moffatt P, Roughley P, Glorieux FH, Rauch F (2014) Normal bone density and fat mass in heterozygous SERPINF1 mutation carriers. J Clin Endocrinol Metab 99:E2446–E2450

    Article  CAS  PubMed  Google Scholar 

  8. Kalkwarf HJ, Zemel BS, Yolton K, Heubi JE (2013) Bone mineral content and density of the lumbar spine of infants and toddlers: influence of age, sex, race, growth, and human milk feeding. J Bone Miner Res 28:206–212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, Frederick MM, Huang X, Lu M, Mahboubi S, Hangartner T, Winer KK (2011) Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab 96:3160–3169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM (2000) Normative data for iliac bone histomorphometry in growing children. Bone 26:103–109

    Article  CAS  PubMed  Google Scholar 

  11. Rauch F, Lalic L, Glorieux FH, Moffatt P, Roughley P (2014) Targeted sequencing of a pediatric metabolic bone gene panel using a desktop semiconductor next-generation sequencer. Calcif Tissue Int 95:323–331

    Article  CAS  PubMed  Google Scholar 

  12. Schleit J, Bailey SS, Tran T, Chen D, Stowers S, Schwarze U, Byers PH (2015) Molecular outcome, prediction, and clinical consequences of splice variants in COL1A1, which encodes the proalpha1(I) chains of type I procollagen. Hum Mutat 36:728–739

    Article  CAS  PubMed  Google Scholar 

  13. Meyer C, Notari L, Becerra SP (2002) Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 277:45400–45407

    Article  CAS  PubMed  Google Scholar 

  14. Fratzl-Zelman N, Schmidt I, Roschger P, Roschger A, Glorieux FH, Klaushofer K, Wagermaier W, Rauch F, Fratzl P (2015) Unique micro- and nano-scale mineralization pattern of human osteogenesis imperfecta type VI bone. Bone 73:233–241

    Article  CAS  PubMed  Google Scholar 

  15. Roschger P, Fratzl-Zelman N, Misof BM, Glorieux FH, Klaushofer K, Rauch F (2008) Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations. Calcif Tissue Int 82:263–270

    Article  CAS  PubMed  Google Scholar 

  16. Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O (2014) Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis 9:145

    Article  PubMed  PubMed Central  Google Scholar 

  17. Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JE, Bolognese MA, Daizadeh N, Valter I, Zerbini CA, Dempster DW (2014) Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res 29:2051–2056

    Article  CAS  PubMed  Google Scholar 

  18. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980

    Article  CAS  PubMed  Google Scholar 

Web Resources

Download references

Acknowledgments

This study was supported by the Shriners of North America and the Fonds de recherche du Québec—Santé. We thank Mark Lepik for the preparation of the figures and Patty Mason for technical assistance. F.R. received support from the Chercheur-Boursier Clinicien program of the Fonds de Recherche du Québec—Santé. This study was supported by the Shriners of North America.

Author information

Authors and Affiliations

  1. Childrens Hospital of Eastern Ontario, Ottawa, ON, Canada

    Leanne Ward

  2. Shriners Hospital for Children and McGill University, 1529 Cedar Avenue, Montreal, QC, H3G 1A6, Canada

    Ghalib Bardai, Pierre Moffatt, Hadil Al-Jallad, Pamela Trejo, Francis H Glorieux & Frank Rauch

Authors
  1. Leanne Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ghalib Bardai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Moffatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hadil Al-Jallad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pamela Trejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francis H Glorieux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Frank Rauch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Rauch.

Ethics declarations

Conflict of Interests

Frank Rauch received support from the Chercheur-Boursier Clinicien program of the Fonds de Recherche du Québec—Santé and has received consultancy fees from Genzyme Inc and Alexion Inc. Francis H Glorieux has received consultancy fees from Novartis Inc, Amgen Inc and Alexion Inc. Leanne Ward, Ghalib Bardai, Pierre Moffatt, Hadil Al-Jallad, and Pamela Trejo declare no conflict of interest.

Human and Animal Rights and Informed Consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from study participants or the legal guardians.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ward, L., Bardai, G., Moffatt, P. et al. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada. Calcif Tissue Int 98, 566–572 (2016). https://doi.org/10.1007/s00223-016-0110-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-016-0110-1

Keywords

Search

Navigation